Found: 6
Select item for more details and to access through your institution.
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 9, p. 1, doi. 10.1038/s41408-022-00723-4
- By:
- Publication type:
- Article
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities.
- Published in:
- Cancers, 2023, v. 15, n. 22, p. 5443, doi. 10.3390/cancers15225443
- By:
- Publication type:
- Article
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands.
- Published in:
- Cancers, 2023, v. 15, n. 17, p. 4334, doi. 10.3390/cancers15174334
- By:
- Publication type:
- Article
Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach.
- Published in:
- Cancers, 2022, v. 14, n. 8, p. 1857, doi. 10.3390/cancers14081857
- By:
- Publication type:
- Article
A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 1, p. 108, doi. 10.1002/hon.3089
- By:
- Publication type:
- Article
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.
- Published in:
- Neuro-Oncology, 2024, v. 26, n. 4, p. 724, doi. 10.1093/neuonc/noad224
- By:
- Publication type:
- Article